BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: BYL-719 (alpelisib)|DRUG: Nab-paclitaxel
Sponsor: Priyanka Sharma
Collaborators: Novartis Pharmaceuticals